Literature DB >> 9835507

Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.

A L Baltch1, R P Smith, M A Franke, P B Michelsen.   

Abstract

The antibacterial activities of levofloxacin, erythromycin, and rifampin against intracellular Legionella pneumophila L-1033, serogroup 1, were studied. In an in vitro system utilizing adherent human monocytes, L. pneumophila L-1033, a phagocytosis time period of 1 h, and antibiotic (levofloxacin, erythromycin, and/or rifampin) at 1 to 10 times the MIC, the CFU/ml values for the monocyte lysate were determined during 0- to 4-day time periods. The decrease in CFU/ml with levofloxacin at pH 7.4 was rapid, occurring within 24 h, and was drug concentration dependent (P < 0.01). The decrease in CFU with rifampin was first observed at 48 h (P < 0.01), while only a minimal decrease in CFU/ml was observed with erythromycin. Combination of levofloxacin and rifampin and of levofloxacin and erythromycin at ten times their MICs significantly decreased the CFU/ml value (P < 0.01), to the value attained by levofloxacin alone, while combination of rifampin and erythromycin did not. Removal of levofloxacin after 24 h of incubation resulted in regrowth of L. pneumophila L-1033, while a continued slow decrease in CFU/ml was seen following rifampin removal; CFU/ml values were unaffected by the removal of erythromycin. At 4 days, and even in assays performed following antibiotic removal, the CFU/ml value continued to be lower in the levofloxacin and rifampin assays than in the assays with erythromycin. Levofloxacin had a significantly higher bactericidal activity against L. pneumophila L-1033 than erythromycin or rifampin. In these assays, the addition of erythromycin or rifampin did not affect the antibacterial activity of levofloxacin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835507      PMCID: PMC106015     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Weidenfeld; M B Dorr
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Phagocytosis of microorganisms.

Authors:  M A Horwitz
Journal:  Rev Infect Dis       Date:  1982 Jan-Feb

3.  General pharmacology of the new quinolone antibacterial agent levofloxacin.

Authors:  K Takasuna; Y Kasai; C Usui; M Takahashi; M Hirohashi; K Tamura; S Takayama
Journal:  Arzneimittelforschung       Date:  1992-03

4.  Effect of levofloxacin, erythromycin or rifampicin pretreatment on growth of Legionella pneumophila in human monocytes.

Authors:  R P Smith; A L Baltch; M Franke; W Hioe; W Ritz; P Michelsen
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

5.  In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; K H Lehr; J Ren
Journal:  J Antimicrob Chemother       Date:  1996-01       Impact factor: 5.790

6.  Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.

Authors:  J L Vildé; E Dournon; P Rajagopalan
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

7.  Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila.

Authors:  D Havlichek; L Saravolatz; D Pohlod
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 8.  Speculations on the influence of infecting phenotype on virulence and antibiotic susceptibility of Legionella pneumophila.

Authors:  J Barker; M R Brown
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

9.  Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions.

Authors:  D M Liebers; A L Baltch; R P Smith; M C Hammer; J V Conroy
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

10.  Characterization of avirulent mutant Legionella pneumophila that survive but do not multiply within human monocytes.

Authors:  M A Horwitz
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  5 in total

1.  Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Authors:  A Trampuz; M Wenk; Z Rajacic; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  High-Throughput Intracellular Antimicrobial Susceptibility Testing of Legionella pneumophila.

Authors:  Lucius Chiaraviglio; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

3.  Selection of suitable reference genes for gene expression studies in Staphylococcus capitis during growth under erythromycin stress.

Authors:  Bintao Cui; Peter M Smooker; Duncan A Rouch; Margaret A Deighton
Journal:  Mol Genet Genomics       Date:  2016-03-21       Impact factor: 3.291

Review 4.  Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias.

Authors:  Burke A Cunha
Journal:  Infect Dis Clin North Am       Date:  2010-03       Impact factor: 5.982

5.  Legionella suppresses the host unfolded protein response via multiple mechanisms.

Authors:  Sean Treacy-Abarca; Shaeri Mukherjee
Journal:  Nat Commun       Date:  2015-07-29       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.